GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response, today announced the closing of its previously announced upsized initial public offering of 7,441,650 shares of its common stock at a price to the public of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase 970,650 additional shares. Including the option exercise, the gross proceeds to NexImmune from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $126.5 million.
This is the first time LLS has participated in an initial public offering through an investment with our Therapy Acceleration Program® (TAP) venture philanthropy initiative.
LLS first partnered with NexImmune in October 2017 through our Therapy Acceleration Program® (TAP) to support the preclinical and clinical development of novel T cell therapy programs, NEXI-001 and NEXI-002, in Phase 1/2 clinical trials for the treatment of relapsed AML after allo-HSCT and multiple myeloma refractory to at least three prior lines of therapy.